Story

BTIG Reiterates Buy on BillionToOne, Citing Strong Fundamentals Despite Post-Earnings Stock Drop

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
BTIG Reiterates Buy on BillionToOne, Citing Strong Fundamentals Despite Post-Earnings Stock Drop
Text size
Background

Investment firm BTIG has reiterated its Buy rating for BillionToOne, Inc., maintaining the company as its top pick in the diagnostics sector even as its shares fell sharply following its latest earnings release. While lowering its price target, BTIG's analysis points to the company's strong fundamental performance and technological advantages as key reasons for its positive outlook.

Quarterly Results and Market Reaction

BillionToOne reported second-quarter fiscal 2026 revenue of $109.4 million, a 64% increase year-over-year that was in line with analyst expectations. Despite meeting consensus, the company's shares plunged 28% in after-hours trading.

According to the report, the market's reaction was driven by two key factors:

  • A decline in revenue from "true-ups," which fell to $2.8 million from $9.2 million in the previous quarter.
  • A one-time issue with a large national payer that has delayed the recognition of over $10 million in claims. BillionToOne's management confirmed this revenue is not lost and is expected to be collected in the third or fourth quarter.

Underlying Growth and Company Outlook

Sample IUX Markets – In-articleAd

Despite the temporary revenue headwind, BillionToOne's operational metrics showed continued strength. Second-quarter prenatal testing volumes grew 31% year-over-year to approximately 181,000, beating analyst estimates of 179,000.

The company reaffirmed its full-year 2026 revenue guidance of $450 million to $465 million, which represents growth of 48% to 52%. BillionToOne also highlighted operational progress, including hiring 70 sales representatives in the first half of the year and completing its Epic Aura integration ahead of schedule.

Analyst Justification

BTIG noted that it ranks BillionToOne in the top decile of specialty labs based on its technology platform and financial profile. The firm adjusted its price target on the stock to $130 from a previous $142.

This valuation is based on applying an 11.5x multiple to BTIG's 2028 revenue estimate of $780 million for the company. The firm's analysis suggests that the recent stock volatility overlooks the company's solid growth trajectory and upcoming product enhancements, including an expansion of its UNITY Fetal risk screen.

Read next

More on Stocks
Back to latest news

LATEST